Sociedad Americana de Hirudoterapia

Ciprofloxacin-resistant Aeromonas hydrophila infection following leech therapy

Case report/review published in J Plast Reconstr Aesthet Surg (2012)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Case reportResistencia antimicrobianaSeguridad y control de infeccionesPatel KM et al. · Journal of plastic, reconstructive & aesthetic surgery, 2012

Abstract

Compromised flap perfusion can lead to the use of leech therapy to aid in flap salvage. Aeromonas hydrophila, a symbiont of the leech, is a well-known bacterial pathogen that has the potential to cause infection in patients receiving leech therapy. Ciprofloxacin is commonly regarded as the antibiotic of choice for prophylaxis against this pathogen. We present patient who underwent leech therapy during salvage attempts for a venous congested flap. A resultant infection developed despite being on appropriate antibiotics. Culture sensitivities indicated that A. hydrophila was resistant to ciprofloxacin.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeCase ReportsJournal ArticleReview
Indexed MeSH termsAeromonas hydrophilaAnti-Bacterial AgentsAntibiotic ProphylaxisAztreonamCiprofloxacinDrug Resistance, BacterialFemaleGram-Negative Bacterial InfectionsHumansLeechingMiddle Aged

Resumen

Patient with venous-congested flap developed ciprofloxacin-resistant A. hydrophila infection despite appropriate prophylaxis. Review of literature on emerging resistance.

Por qué esto importa para la hirudoterapia

This case report describes a patient who developed an Aeromonas hydrophila infection during leech therapy for a venous congested flap, despite receiving what was considered appropriate ciprofloxacin prophylaxis. Culture sensitivities confirmed the A. hydrophila strain was resistant to ciprofloxacin, the commonly regarded antibiotic of choice for prophylaxis against this pathogen. This is directly relevant to ASH's domain, documenting prophylaxis failure due to resistance and raising concern about relying solely on ciprofloxacin for Aeromonas coverage during hirudotherapy. The limitation is that this is a single case report with no broader epidemiological or resistance surveillance data.

Citación

Ciprofloxacin-resistant Aeromonas hydrophila infection following leech therapy: a case report and review of the literature.

Patel KM et al. · Journal of plastic, reconstructive & aesthetic surgery, 2012

Contexto clínico relacionado

Explore cómo esta investigación se conecta con la práctica clínica

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.